20 October 2026
Incanthera plc
("Incanthera" or the "Company")
Notice of AGM and publication of Annual Report and Accounts
Incanthera plc (AQSE: INC), the specialist company focused on innovative technologies in dermatology and oncology, announces that its Annual General Meeting (AGM) will be held at 11:00 a.m. on Friday, 13 November 2026 at the offices of Gateley Plc at 1 Paternoster Square,
The full Notice of AGM is available to view and download from the Company's website here: https://www.incanthera.com/investors/shareholder-information/agm/
The Company's Annual Report and Accounts for the year ended 31 March 2026 have been posted to shareholders and can also be found on the Company's website here: https://www.incanthera.com/investors/results-reports-and-presentations/
-ENDS-
For further enquiries:
|
Incanthera plc Stuart Robertson, CEO Laura Brogden, CFO & Company Secretary |
Via Vigo Consulting |
|
|
|
|
Cairn Financial Advisers LLP (Aquis Exchange Corporate Adviser) Jo Turner / Liam Murray / Ed Downes |
+44 (0) 20 7213 0880 |
|
|
|
|
Stanford Capital Partners Ltd (Broker) Patrick Claridge / Bob Pountney |
+44 (0) 20 7628 5582 |
|
|
|
|
Vigo Consulting (Financial PR and Investor Relations) Jeremy Garcia / Rozi Morris |
+44 (0) 20 7390 0230 incanthera@vigoconsulting.com |
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company started as a spin-out from the Institute of Cancer Therapeutics ("ICT") at the University of
For more information on the Company please visit: www.incanthera.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
